Ezetimibe Livraison Le Lendemain
Note 4.8 étoiles, basé sur 224 commentaires.
In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on Ezetimibe Livraison Le Lendemain cycle length in girls.
Also, Ezetimibe has not been studied in patients younger than 10 years of age or in pre-menarcheal girls. No overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology In the Study of Heart and Renal Protection SHARP trial of patients with moderate to severe renal impairment non-dialysis patients with median serum creatinine 2.
However, because renal impairment is a risk factor for statin-associated myopathy, doses of simvastatin exceeding 20 mg should be used with caution and close monitoring when administered concomitantly with Ezetimibe in patients with moderate to severe renal impairment.
In the event of an overdose, symptomatic and supportive measures should be employed, Ezetimibe Livraison Le Lendemain. Ezetimibe Description Ezetimibe is in a Ezetimibe Livraison Le Lendemain of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. The chemical name of Ezetimibe is 1- 4-fluorophenyl – 3 R -[3- 4-fluorophenyl -3 S -hydroxypropyl]-4 S – 4-hydroxyphenyl azetidinone.
Its molecular weight is Ezetimibe, USP is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water.
Ezetimibe tablets, USP are available as a tablet for oral administration containing 10 mg of Ezetimibe, USP and the following inactive ingredients: Ezetimibe – Clinical Pharmacology Ezetimibe had no Ezetimibe Livraison Le Lendemain meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E in a study of patientsand did not impair adrenocortical steroid hormone production in a study of patients.
The cholesterol content of the liver is derived predominantly from three sources. The liver can synthesize cholesterol, take up cholesterol from the blood from circulating lipoproteins, or take up cholesterol absorbed by the small intestine. Intestinal cholesterol is derived primarily from cholesterol secreted in the bile and from dietary cholesterol.
Ezetimibe has Ezetimibe Livraison Le Lendemain mechanism of action that differs from those of other classes of cholesterol-reducing compounds statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols.
The molecular target of Ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 NPC1L1which is involved in the intestinal uptake of cholesterol and phytosterols.
Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion.
Instead, Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins and of fenofibrate [see Clinical Studies In addition, decreased levels of HDL-C are associated with the development of atherosclerosis.
Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, cholesterol-enriched Ezetimibe Livraison Le Lendemain lipoproteins, Ezetimibe Livraison Le Lendemain, including very-low-density lipoproteins VLDLintermediate-density lipoproteins IDLand remnants, can also promote atherosclerosis.
Indications and Usage for Ezetimibe
The independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined. The effects of Ezetimibe given either alone or in addition to a statin or fenofibrate on cardiovascular morbidity and mortality have not been established.
After a single mg dose of Ezetimibe to fasted adults, mean Ezetimibe peak plasma concentrations C max of 3. There was no substantial deviation from dose proportionality between 5 and 20 mg.
The absolute bioavailability of Ezetimibe cannot Ezetimibe Livraison Le Lendemain determined, as the compound is virtually insoluble in aqueous media suitable for injection. Effect of Food on Oral Absorption Concomitant food administration high-fat or non-fat meals had no effect on the extent of absorption of Ezetimibe when administered as Ezetimibe mg tablets.
Ezetimibe can be administered with or without food. Metabolism and Excretion Ezetimibe is primarily metabolized in the small Ezetimibe Livraison Le Lendemain and liver via glucuronide conjugation a phase II reaction with subsequent biliary and renal excretion.
Minimal oxidative metabolism a phase I reaction has been observed in all species evaluated. In humans, Ezetimibe is rapidly metabolized to Ezetimibe-glucuronide.
Both Ezetimibe and Ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both Ezetimibe and Ezetimibe-glucuronide. Plasma concentration-time profiles exhibit multiple peaks, suggesting Ezetimibe Livraison Le Lendemain recycling, Ezetimibe Livraison Le Lendemain. After 48 hours, there were no detectable levels of radioactivity in the plasma.
Specific Populations Geriatric Patients: Based on a meta-analysis of multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences between Black and Caucasian subjects. Studies in Asian subjects indicated that the pharmacokinetics of Ezetimibe were similar to those seen in Caucasian subjects.
Garantie de remboursement – Simvastatin livraison le lendemain – Sans Ordonnance
After a single mg dose of Ezetimibe, the mean AUC for total Ezetimibe was increased approximately 1. The mean AUC values for total Ezetimibe and Ezetimibe were increased approximately 3- to 4-fold and 5- to 6-fold, respectively, in patients with moderate Child-Pugh score 7 to 9 or severe hepatic impairment Child-Pugh score 10 to Ezetimibe Livraison Le Lendemain In a day, multiple-dose study 10 mg daily in patients with moderate hepatic impairment, the mean AUC values for total Ezetimibe and Ezetimibe were increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects.
Due to the unknown effects of the increased exposure to Ezetimibe in patients with moderate or severe hepatic impairment, Ezetimibe is not recommended in these patients [see Warnings and Precautions 5. This indicates that Ezetimibe is neither an inhibitor nor an inducer of these cytochrome P isozymes, and it is unlikely that Ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes, Ezetimibe Livraison Le Lendemain.